Recently, several management personnel of Olympus in the United States have been promoted to senior positions in the world. The appointment will take effect on April 1, 2019, which indicates that Olympus is starting the globalization process.

Nacho Abia will serve as the co-director of the newly formed Therapeutic Solutions division, based on the President and CEO of Olympus Corporation of the Americas (OCA). Olympus said in a statement: Nacho Abia will be responsible for the global business development of the three core businesses of medical , scientific and imaging in a new position.

Nacho Abia's colleague, Tomohisa Sakurai, was appointed as the co-director of the therapeutic solutions division and was transferred from Tokyo headquarters to Olympus Americas in Center Valley, Pennsylvania, in 2018.

In addition, Richard Lebitz, currently an executive director of OCA's internal audit, will be promoted to the Olympus global chief audit officer.

Mark Miller was selected as the chief communications officer of Olympus and will serve as the regional communications director for the Americas.

In another statement, Olympus announced other efforts to transform, including reorganizing the medical business into two global divisions – the Endoscopic Solutions division and treatment solutions ( Therapeutic Solutions) department.

The Endoscopy Solutions division will continue to be managed by Japan, while the faster treatment solutions for the product lifecycle are regulated by the US because the US is the world's largest market for therapeutic devices .

In addition, according to Reuters, Olympus also announced that it will propose to a radical shareholder, US hedge fund ValueAct Capital, a board of directors, which currently holds 5.04% of Olympus tradable shares, despite such investments In Japan, it is widely regarded as “asset-strippers to be resisted”, but Olympus has taken this measure.

Olympus also plans to nominate ValueHect partner Rob Hale as a director, which will need to be approved at the June 2019 general meeting, which is part of Olympus' efforts to strengthen global management. According to reports, Olympus will also seek the opinions of ValueAct to decide whether to add two more director positions.

As one of the initiatives, Vice President Yasuo Takeuchi will also be promoted to CEO on April 1, 2019, and Hiroyuki Sasa, the current president of Olympus CEO in 2012, will become a board member.

In December 2018, Olympus and the US Department of Justice filed and supplemented the TJF-Q180V duodenoscopy medical report and continued to sell the device during this period, reaching a final plea agreement and becoming the focus of the news.

Olympus admitted in a statement that it failed to submit two necessary supplemental MDR (Medical Device Reporting) and an initial MDR to the FDA. From 2012 to 2014, due to equipment problems, patients developed a series of diseases. Some of these diseases have proven to be fatal.

According to Reuters, former Olympus executive Hisao Yabe admitted to selling counterfeit equipment, the trial will be held on March 27, 2019, and Hisao Yabe faces a one-year prison sentence.

Wireless Video Intercom System

Wireless Video Intercom System,Wireless Video Intercom,Wireless Video Door Phone,Wireless Door Intercom System

Zhuhai Mingke Electronics Technology Co., Ltd , https://www.zhmkdz-electronics.com